Neuland Laboratories Ltd. (IN:NEULANDLAB)
:NEULANDLAB
Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹15265.60
₹591.15(4.14%)
At close: 4:00 PM EST
₹15265.60
₹591.15(4.14%)
Day’s Range― - ―
52-Week Range₹11,022.40 - ₹19,748.40
Previous CloseN/A
Volume58.52K
Average Volume (3M)2.41K
Market Cap
₹209.50B
Enterprise Value₹212.75B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹2.65B
Price to Earnings (P/E)42.4
Beta1.25
Next Earnings
Jul 30, 2026EPS Estimate
60.52Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)187.17
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)338.23
Revenue Forecast (FY)₹22.42B
Bulls Say, Bears Say
Bulls Say
Profitability & MarginsConsistent mid-to-high teens net margins and robust EBIT margins signal durable core profitability. This margin base supports reinvestment in process R&D and scale-up, provides a cushion against industry cyclicality, and underpins sustainable earnings over the coming months.
Conservative Balance SheetA low debt-to-equity ratio and steady equity growth indicate financial conservatism and flexibility. This positioning helps absorb working-capital volatility, supports bidding on long-term CDMO contracts, and reduces refinancing risk over a multi-month horizon.
Specialized CDMO/API CapabilitiesTechnical expertise in complex small-molecule chemistry and end-to-end process development creates high barriers to entry. These capabilities foster long-term client relationships, recurring commercial supply opportunities, and structural revenue durability versus simpler commodity APIs.
Bears Say
Weaker Cash-flow ConversionDespite positive reported profits, conversion to cash is only moderate and free cash flow fell negative in FY2026. This reduces internal funding for capex, working capital or dividends, increases reliance on financing, and raises vulnerability to margin or demand shocks over months.
Margin Compression RiskA sharp decline in gross margins signals input-cost or product-mix pressure that can persist. Structural margin erosion weakens project economics for CDMO work, reduces cash generation capacity, and may force pricing or cost adjustments that constrain medium-term profitability.
Rising Absolute DebtWhile leverage remains low in ratio terms, rising absolute debt in FY2026 reduces financial headroom amid margin pressure. This increases sensitivity to cash-flow variability, may raise interest costs, and could constrain timing of strategic capacity investments or client-funded projects.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹11022.40 and its highest was ₹19748.40 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹209.50B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 70 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on May 12, 2026. The company reported ₹165.76 earnings per share for the quarter, beating the consensus estimate of ₹78.16 by ₹87.6.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 60.52.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹165.76 in its last earnings report, beating expectations of ₹78.16. Following the earnings report the stock price went down -3.121%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Glenmark Life Sciences Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―